肠道菌群在实体瘤免疫治疗中的进展
Progression of Gut Microbiota in Immunotherapy for Solid Tumors
摘要: 近年来免疫治疗在肿瘤的治疗中取得了非常大的突破，但并非所有患者都能够从这一种治疗方法中获益，因此需要探索新的策略来增强免疫治疗的效果。既往研究表明，粪便菌群移植(faecal microbiota transplantation, FMT)可以提高晚期黑色素瘤患者免疫治疗的疗效。通过改变肠道微生物群和增强患者的免疫反应来提高免疫疗法的效果。尽管前景广阔，但要提高FMT在肿瘤治疗中的疗效，并进一步了解这种治疗策略可能存在的优缺点，还需要进行更多的研究。因此本文就肠道菌群在实体瘤免疫治疗中的进展进行综述。
Abstract: In recent years, immunotherapy has made great breakthroughs in the treatment of tumors, but not all patients can benefit from this treatment, so new strategies need to be explored to enhance the effect of immunotherapy. Previous studies have shown that fecal microbiota transplantation (FMT) can improve the efficacy of immunotherapy in patients with advanced melanoma. The effect of immunotherapy can be improved by changing the intestinal microbiota and enhancing the immune response of patients. Although promising, more research is needed to improve the efficacy of FMT in cancer treatment and to further understand the possible advantages and disadvantages of this treatment strategy. Therefore, this article reviews the progress of intestinal microbiota in the immunotherapy of solid tumors.
文章引用：张慧云. 肠道菌群在实体瘤免疫治疗中的进展[J]. 临床医学进展, 2024, 14(11): 816-821. https://doi.org/10.12677/acm.2024.14112950

参考文献

[1] Lee, K.A., Luong, M.K., Shaw, H., Nathan, P., Bataille, V. and Spector, T.D. (2021) The Gut Microbiome: What the Oncologist Ought to Know. British Journal of Cancer, 125, 1197-1209. [Google Scholar] [CrossRef] [PubMed]
[2] Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M., et al. (2018) The Commensal Microbiome Is Associated with Anti-PD-1 Efficacy in Metastatic Melanoma Patients. Science, 359, 104-108. [Google Scholar] [CrossRef] [PubMed]
[3] Yarchoan, M., Hopkins, A. and Jaffee, E.M. (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. New England Journal of Medicine, 377, 2500-2501. [Google Scholar] [CrossRef] [PubMed]
[4] Ma, Y., Li, J., Wang, H., Chiu, Y., Kingsley, C.V., Fry, D., et al. (2020) Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology, 159, 306-319.e12. [Google Scholar] [CrossRef] [PubMed]
[5] Andrews, M.C., Duong, C.P.M., Gopalakrishnan, V., Iebba, V., Chen, W., Derosa, L., et al. (2021) Gut Microbiota Signatures Are Associated with Toxicity to Combined CTLA-4 and PD-1 Blockade. Nature Medicine, 27, 1432-1441. [Google Scholar] [CrossRef] [PubMed]
[6] Santoni, M., Piva, F., Conti, A., Santoni, A., Cimadamore, A., Scarpelli, M., et al. (2018) Re: Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. European Urology, 74, 521-522. [Google Scholar] [CrossRef] [PubMed]
[7] Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., et al. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science, 359, 91-97. [Google Scholar] [CrossRef] [PubMed]
[8] Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., et al. (2018) Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science, 359, 97-103. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, K., Kwon, O., Ryu, T.Y., Jung, C.-R.J., Min, J.-K., Kim, D.-S., Son, M.-Y. and Cho, H.-S. (2019) Propionate of a Microbiota Metabolite Induces Cell Apoptosis and Cell Cycle Arrest in Lung Cancer. Molecular Medicine Reports, 20, 1569-1574.
[10] Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., et al. (2019) Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. The Oncologist, 25, 55-63. [Google Scholar] [CrossRef] [PubMed]
[11] Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. (2015) Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science, 350, 1084-1089. [Google Scholar] [CrossRef] [PubMed]
[12] Mycko, M.P., Cichalewska, M., Cwiklinska, H. and Selmaj, K.W. (2015) miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40. The Journal of Neuroscience, 35, 16504-16515. [Google Scholar] [CrossRef] [PubMed]
[13] Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J., Morrison, R.M., et al. (2021) Fecal Microbiota Transplant Overcomes Resistance to Anti-Pd-1 Therapy in Melanoma Patients. Science, 371, 595-602. [Google Scholar] [CrossRef] [PubMed]
[14] Horn, V. and Sonnenberg, G.F. (2024) Group 3 Innate Lymphoid Cells in Intestinal Health and Disease. Nature Reviews Gastroenterology & Hepatology, 21, 428-443. [Google Scholar] [CrossRef] [PubMed]
[15] Zheng, Y., Fang, Z., Xue, Y., Zhang, J., Zhu, J., Gao, R., et al. (2020) Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer. Gut Microbes, 11, 1030-1042. [Google Scholar] [CrossRef] [PubMed]
[16] 袁文杰, 郭亚琼, 韩毅, 等. 非小细胞肺癌患者肠道微生物特征分析[J]. 微生物学报, 2021, 61(9): 2776-2790.
[17] Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., et al. (2019) Gut Microbiome Affects the Response to Anti-PD-1 Immunotherapy in Patients with Hepatocellular Carcinoma. Journal for ImmunoTherapy of Cancer, 7, Article No. 193. [Google Scholar] [CrossRef] [PubMed]
[18] Tomita, Y., Ikeda, T., Sakata, S., Saruwatari, K., Sato, R., Iyama, S., et al. (2020) Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. Cancer Immunology Research, 8, 1236-1242. [Google Scholar] [CrossRef] [PubMed]
[19] Hanahan, D. (2022) Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12, 31-46. [Google Scholar] [CrossRef] [PubMed]
[20] Helmink, B.A., Khan, M.A.W., Hermann, A., Gopalakrishnan, V. and Wargo, J.A. (2019) The Microbiome, Cancer, and Cancer Therapy. Nature Medicine, 25, 377-388. [Google Scholar] [CrossRef] [PubMed]
[21] Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., et al. (2021) Clinical Impact of Probiotics on the Efficacy of Anti‐PD‐1 Monotherapy in Patients with Nonsmall Cell Lung Cancer: A Multicenter Retrospective Survival Analysis Study with Inverse Probability of Treatment Weighting. International Journal of Cancer, 149, 473-482. [Google Scholar] [CrossRef] [PubMed]
[22] Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., et al. (2022) Nivolumab plus Ipilimumab with or without Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma: A Randomized Phase 1 Trial. Nature Medicine, 28, 704-712. [Google Scholar] [CrossRef] [PubMed]
[23] Lythgoe, M.P., Mullish, B.H., Frampton, A.E. and Krell, J. (2022) Polymorphic Microbes: A New Emerging Hallmark of Cancer. Trends in Microbiology, 30, 1131-1134. [Google Scholar] [CrossRef] [PubMed]
[24] Hefazi, M., Patnaik, M.M., Hogan, W.J., Litzow, M.R., Pardi, D.S. and Khanna, S. (2017) Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection in Patients with Cancer Treated with Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clinic Proceedings, 92, 1617-1624. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, D., Wu, J., Jin, D., Wang, B. and Cao, H. (2018) Fecal Microbiota Transplantation in Cancer Management: Current Status and Perspectives. International Journal of Cancer, 145, 2021-2031. [Google Scholar] [CrossRef] [PubMed]
[26] Maleki, S., Lenehan, J., Burton, J., Silverman, M., Parvathy, S.N., El-Hajjar, M., et al. (2020) P864 Combination of Fecal Microbiota Transplantation from Healthy Donors with Anti-PD1 Immunotherapy in Treatment-Naïve Advanced or Metastatic Melanoma Patients. Journal for ImmunoTherapy of Cancer, 8, A11. [Google Scholar] [CrossRef] 
[27] Zhao, W., Lei, J., Ke, S., Chen, Y., Xiao, J., Tang, Z., et al. (2023) Fecal Microbiota Transplantation plus Tislelizumab and Fruquintinib in Refractory Microsatellite Stable Metastatic Colorectal Cancer: An Open-Label, Single-Arm, Phase II Trial (RENMIN-215). eClinicalMedicine, 66, Article ID: 102315. [Google Scholar] [CrossRef] [PubMed]
[28] Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., et al. (2019) Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 178, 795-806.e12. [Google Scholar] [CrossRef] [PubMed]
[29] Tintelnot, J., Xu, Y., Lesker, T.R., Schönlein, M., Konczalla, L., Giannou, A.D., et al. (2023) Microbiota-Derived 3-IAA Influences Chemotherapy Efficacy in Pancreatic Cancer. Nature, 615, 168-174. [Google Scholar] [CrossRef] [PubMed]
[30] Machida, K. and Tahara, S.M. (2022) Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-Like Cells. Cancers, 14, Article No. 2381. [Google Scholar] [CrossRef] [PubMed]

为你推荐